Clinical Outcomes of Eravacycline in Patients Treated Predominately for Carbapenem-Resistant Acinetobacter baumannii

ABSTRACT Forty-six patients were treated with eravacycline (ERV) for Acinetobacter baumannii infections, where 69.5% of isolates were carbapenem resistant (CRAB). Infections were primarily pulmonary (58.3%), and most patients received combination therapy (84.4%). The median (IQR) ERV duration was 6....

Full description

Bibliographic Details
Main Authors: Sara Alosaimy, Taylor Morrisette, Abdalhamid M. Lagnf, Leonor M. Rojas, Madeline A. King, Benjamin M. Pullinger, Athena L. V. Hobbs, Nicholson B. Perkins, Michael P. Veve, Jeannette Bouchard, Tristan Gore, Bruce Jones, James Truong, Justin Andrade, Glen Huang, Reese Cosimi, S. Lena Kang-Birken, Kyle C. Molina, Mark Biagi, Michael Pierce, Marco R. Scipione, Jing J. Zhao, Susan L. Davis, Michael J. Rybak
Format: Article
Language:English
Published: American Society for Microbiology 2022-10-01
Series:Microbiology Spectrum
Subjects:
Online Access:https://journals.asm.org/doi/10.1128/spectrum.00479-22